We rank companies based on fund manager, research analyst and news sentiment
AXNX stock icon

Axonics
AXNX

$66.95
0.15%
 

About: Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.

Employees: 797

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 10 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

192% more call options, than puts

Call options by funds: $8.56M | Put options by funds: $2.94M

100% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 4 (+2) [Q4]

51% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 67

32% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 25

13% more capital invested

Capital invested by funds: $2.81B [Q3] → $3.16B (+$352M) [Q4]

4% more funds holding

Funds holding: 217 [Q3] → 225 (+8) [Q4]

0.82% more ownership

Funds ownership: 99.25% [Q3] → 100.07% (+0.82%) [Q4]

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$63
6%
downside
Avg. target
$71
5%
upside
High target
$75
12%
upside

10 analyst ratings

positive
40%
neutral
60%
negative
0%
RBC Capital
Shagun Singh
6%upside
$71
Sector Perform
Reiterated
29 Feb 2024
Truist Securities
David Rescott
6%upside
$71
Hold
Downgraded
16 Jan 2024
Truist Securities
David Rescott
6%upside
$71
Hold
Downgraded
12 Jan 2024
Piper Sandler
Adam Maeder
6%upside
$71
Neutral
Downgraded
12 Jan 2024
Leerink Partners
Mike Kratky
6%upside
$71
Market Perform
Downgraded
12 Jan 2024

Financial journalist opinion

Based on 4 articles about AXNX published over the past 30 days